Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

PaperCitations, authors & open-access status

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 2,674 citations, 2015 year and closed oa status.

2,674
Citations
2015
Year
closed
OA Status

Related on ScholarIQ

Alan H. Bryce
Author
The Lancet Oncology
Journal
Cancer Immunotherapy and Biomarkers
Topic
Cancer Immunotherapy and Biomarkers
Topic
Immunotherapy and Immune Responses
Topic
Melanoma and MAPK Pathways
Topic
470M+ articles · free account